Counterfeit anti-infective drugs

Lancet Infectious Diseases

Volumn 6, Issue 9, 2006, Pages 602-613

  Newton, Paul N ^a,b   Green, Michael D ^c   Fernández, Facundo M ^d   Day, Nicholas PJ ^a,b,e   White, Nicholas J ^a,b,e  

^a MAHOSOT HOSPITAL   (Laos)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN DERIVATIVE; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTESUNATE; CHLORAMPHENICOL; COTRIMOXAZOLE; HALOFANTRINE; HERBACEOUS AGENT; MEFLOQUINE; OSELTAMIVIR; PARACETAMOL; QUININE; RIFAMPICIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; AVIAN INFLUENZA; DRUG CONTAMINATION; DRUG COST; DRUG DETERMINATION; DRUG FATALITY; DRUG FORMULARY; DRUG HYPERSENSITIVITY; DRUG IMPURITY; DRUG INFORMATION; DRUG MONITORING; DRUG QUALITY; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; FORENSIC IDENTIFICATION; FORGERY; GAS CHROMATOGRAPHY; GOVERNMENT REGULATION; HEALTH CARE POLICY; HEALTH SURVEY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION DISSEMINATION; INFORMATION SERVICE; LEGAL ASPECT; PRIORITY JOURNAL; REVIEW; THIN LAYER CHROMATOGRAPHY; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-INFECTIVE AGENTS; GREAT BRITAIN; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 33747341277     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70581-3     Document Type: Review

References (133)

1. WHO. Combating counterfeit drugs: a concept paper for effective international collaboration. Draft. http://www.who.int/entity/medicines/services/counterfeit/CombatingCounterfeitDrugs_Conceptpaper.pdf (accessed July 16, 2006)
2. Cockburn R., Newton P., Agyarko E., Akunyili D., and White N. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2 (2005) e100
3. Wondemagegnehu E. Counterfeit and substandard drugs in Myanmar and Viet Nam. WHO Report. WHO/EDM/QSM/99.3 (1999), WHO, Geneva
4. Carpenter J., and US Pharmacopeia. A review of drug quality in Asia with focus on anti-infectives. http://www.uspdqi.org/pubs/other/ANEReview.pdf (accessed July 16, 2006)
5. WHO. What encourages counterfeiting of drugs?. http://www.who.int/medicines/services/counterfeit/faqs/16/en/index.html (accessed July 16, 2006)
6. Shakoor O., Taylor R., and Behrens R. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 2 (1997) 839-845
7. Taylor R., Shakoor O., Behrens R., et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357 (2001) 1933-1936
8. WHO. Counterfeit drugs-guidelines for the development of measures to combat counterfeit drugs. WHO/EDM/QSM/99.1 (1999), WHO, Geneva
9. Grieve M. A modern herbal. http://www.botanical.com/botanical/mgmh/v/valeri01.html (accessed July 16, 2006)
10. Anon. HerbWorld medicinal herb facts. http://www.herbnet.com/Herb%20Uses_AB.htm (accessed July 16, 2006)
11. Missouri Botanic Garden. Three centuries of cinchona. Proceedings of the celebration of the 300th anniversary of the first recognised use of cinchona (1931), Missouri Botanic Garden, St Louis, Missouri, USA 29-138
12. Saunders W. Letter from Dr Edward Rigby, Norwich, 8th September 1782. Observations on the superior efficacy of the red Peruvian bark. 4th ed. (1782), J Johnson & J Murray, London, UK 164
13. Heath W. America's first drug regulation regime: the rise and fall of the Import Drug Act of 1848. Food and Drug Law Journal 59 (2004) 169-200
14. Anon. Adulteration of drugs. Lancet 1 (1848) 104
15. Greene G. The third man (1950), Heinemann, London
16. Drazin C. In search of the third man (1999), Methuen, London
17. Anon. The Vienna project. http://www.bfi.org.uk/sightandsound/feature/169 (accessed July 16, 2006)
18. Reidenberg M., and Conner B. Counterfeit and substandard drugs. Clin Pharmacol Ther 69 (2001) 189-193
19. Lybecker K. Rx roulette: counterfeit pharmaceuticals in developing nations, 2003. http://www.lebow.drexel.edu/lybecker/Lybecker.pdf (accessed July 16, 2006)
20. Carpenter J. A matrix of drug quality reports on USAID-assisted countries by the USP Drug Quality and Information Program, 2004. http://www.uspdqi.org/pubs/other/GHC-DrugQualityMatrix.pdf (accessed July 16, 2006)
21. Rudolf P., and Bernstein I. Counterfeit drugs. N Engl J Med 350 (2004) 1384-1386
22. Deisingh A. Pharmaceutical counterfeiting. Analyst 130 (2005) 271-279
23. ten Ham M. Counterfeit drugs: implications for health. Adverse Drug React Toxicol Rev 11 (1992) 59-65
24. Harper J. Counterfeit medicines survey report, Council for Europe (2006), Council of Europe Publishing, Strasbourg
25. Anon. Thirteen fake bird flu vaccine-makers punished. http://news.xinhuanet.com/english/2005-11/07/content_3745572.htm (accessed July 16, 2006)
26. Saywell T., and McManus J. What's in that pill?. Far Eastern Economic Review (Feb 21, 2002) 34-40
27. Hanif M., Mobarak M., Ronan A., Rahman D., Donovan J., and Bennish M. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. BMJ 311 (1995) 88-91
28. O'Brien K., Selanikio J., Hecdivert C., et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA 279 (1998) 1175-1180
29. Singh J., Dutta A., Khare S., et al. Diethylene glycol poisoning in Gurgaon, India, 1998. Bull World Health Organ 79 (2001) 88-95
30. Day J., Hien T., and Farrar J. Expiry-date tampering. Lancet 363 (2004) 172
31. Baikait R. Unsafe injections blamed for 1.3 million premature deaths annually. Pharmabiz (Mumbai) (May 21, 2003)
32. Rozendaal J. Fake antimalarials circulating in Cambodia. Mekong Malaria Forum 7 (2000) 62-69
33. Francis P. The tip of an iceberg. Pharmabiz (Mumbai) (May 15, 2003)
34. Moken M. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices. Am J Law Med 29 (2003) 525-542
35. Eban K. Dangerous Doses. How counterfeiters are contaminating America's drug supply (2005), Harcourt Inc, Orlando, USA
36. WHO. World Health Organisation counterfeit drug reports: 1999 - October 2000. www.who.int/medicines/library/pnewslet/pn300cfd.html (accessed June 17, 2003)
37. Rago L. Counterfeit drugs: threat to public health. Global Forum Pharmaceutical AntiCounterfeiting, Geneva, Switzerland, Sept 22-25, 2002.
38. Jähnke R., and Küsters G. Detecting counterfeit drugs-protection against counterfeit medicines using the GPHF-Minilab. Mekong Malaria Forum 8 (2001) 118-124
39. Chakravarty S., Innithan S., and Ram A. Deadly doses. India Today (Jan 29, 2001) 58-61
40. Mukerjee A. Pills that kill. Outlook (Mumbai) (Sept 22, 2003) 46-54
41. Fackler M. China's fake drugs kill thousands. San Francisco Examiner (July 29, 2002)
42. Behrens R., Awad A., and Taylor R. Substandard and counterfeit drugs in developing countries. Trop Doct 32 (2002) 1-2
43. Kron M. Substandard primaquine phosphate for US Peace Corps personnel. Lancet 348 (1996) 1453-1454
44. Kayumba P., Risha P., Shewiyo D., et al. The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. J Clin Pharm Ther 29 (2004) 331-338
45. Syhakhang L., Lundborg C., Lindgren B., and Tomson G. The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999. Pharm World Sci 26 (2004) 333-338
46. Anon. La qualite des médicaments sur le marche pharmaceutique africain. Etude analytique dans trois pays: Cameroun, Madagascar, Tchad (1995), WHO, Geneva WHO/DAP/95.3
47. Gimenez F., Bruneton C., and Narong Rith D. Etude de la qualité des médicaments vendus et dispenses au Cambodge. Med Mal Infect 27 (1997) 541-544
48. Stenson B., Lindgren B., Syhakhang L., and Tomson G. The quality of drugs in private pharmacies in the Lao People's Democratic Republic. Int J Risk Safety Med 11 (1998) 243-249
49. Newton P., Proux S., Green M., et al. Fake artesunate in southeast Asia. Lancet 357 (2001) 1948-1950
50. Prazuck T., Falconi I., Morineau G., Bricard-Pacaud V., Lecomte A., and Ballereau F. Quality control of antibiotics before the implementation of an STD program in northern Myanmar. Sex Transm Dis 29 (2002) 624-627
51. Sow P., Gueye T., Sy E., et al. Drugs used in the parallel market for the treatment of urethral discharge in Dakar: epidemiologic investigation and physicochemical tests. Int J Infect Dis 6 (2002) 108-112
52. Maponga C., and Ondari C. The quality of antimalarials. A study in selected African countries (2003), WHO, Geneva WHO/EDM/PAR.2003.4
53. Penzak S., Acosta E., Tavel J., and Masur H. Analysis of generic nevirapine products in developing countries. JAMA 289 (2003) 2648-2649
54. Iqbal M., Hakimm S., Hussain A., Mirza Z., Qureshi F., and Abdulla E. Ofloxacin: laboratory evaluation of the antibacterial activity of 34 brands representing 31 manufacturers available in Pakistan. Pak J Med Sci 20 (2004) 349-356
55. Basco L. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 70 (2004) 245-250
56. Smine A., Phanouvong S., Chanthap L., Tsuyuoka R., Nivana N., and Blum N. Antimalarial drug quality in Mekong countries. http://www.uspdqi.org/pubs/other/AntimalarialPoster.pdf (accessed July 16, 2006)
57. Dondorp A., Newton P., Mayxay M., et al. Fake antimalarials in southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Hlth 9 (2004) 1241-1246
58. Phanouvong S., Reiss S., and Smine A. Why be concerned about the quality of antimalarials and ARV drugs. http://www.uspdqi.org/pubs/other/whyDrugQuality.pdf (accessed July 16, 2006)
59. Anon. Fake anti malaria drugs in Cambodia: a danger to public health. Final Report, NCM - Cambodia, USP, WHO (2005), National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia
60. Legris C. La détection des médicaments contrefaits par investigation de leur authenticité. Étude pilote sur le marché pharmaceutique illicite de Côte d'Ivoire. Thèse pour le diplôme d'état de docteur en pharmacie soutenus à la Faculté de Pharmacie Nancy le 16 decembre 2005. http://www.remed.org/html/theses.html (accessed July 16, 2006)
61. Lon C., Tsuyuoka R., Phanouvong S., et al. Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg. published online June 8, 2006; DOI:doi:10.1016/j.trstmh.2006.01.003
62. Rozendaal J. Fake antimalaria drugs in Cambodia. Lancet 357 (2001) 890
63. Aldhous P. Murder by medicine. Nature 434 (2005) 132-136
64. Alter K., Fernandez F., Green M., and Newton P. Analysis of counterfeit antimalarial drugs. Eur Pharm Rev 3 (2004) 1-5
65. Newton P., Dondorp A., Green M., Mayxay M., and White N. Counterfeit artesunate antimalarials in southeast Asia. Lancet 362 (2003) 169
66. Newton P., McGready R., Fernandez F., et al. Manslaughter by fake artesunate in Asia-will Africa be next?. PLoS Med 3 (2006) e197
67. USP. Fake antimalarials found in Yunnan Province, China. http://www.uspdqi.org/pubs/other/FakeAntimalarialsinChina.pdf (accessed July 16, 2006)
68. Phillips G. World Congress of Pharmacy and Pharmaceutical Sciences: anticounterfeiting measures. Pharm J 271 (2003) 465
69. Risha P., Shewiyo D., Msami A., et al. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop Med Int Health 7 (2002) 701-707
70. Amin A., Snow R., and Kokwaro G. The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector. J Clin Pharm Ther 30 (2005) 559-565
71. Jähnke R., Pachaly P., Gobina N., et al. Concise quality control guide on essential drugs, vol II. Thin layer chromatography (1998), German Pharma Health Fund, Frankfurt
72. Kenyon T., Kenyon A., and Sibiya T. Drug quality screening in developing countries: establishment of an appropriate laboratory in Swaziland. Bull World Health Organ 72 (1994) 615-620
73. Jähnke RW, Küsters G. The GPHF-Minilab project. First Global Forum on Pharmaceutical Anticounterfeiting; Geneva, Switzerland; Sept 22-25, 2002.
74. Jähnke R. Counterfeit medicines and the GPHF-Minilab for rapid drug quality verification. Pharm Ind 66 (2004) 1187-1193
75. el-Ashry S., Aly F., and el-Brashy A. Studies of complex formation between the bromophenol blue and some important aminoquinoline antimalarials. Arch Pharm Res 17 (1994) 415-419
76. Jähnke R., Kallmayer H., Breyer C., et al. Concise quality control guide on essential drugs, vol 1. Colour reactions (1998), German Pharma Health Fund, Frankfurt
77. Green M., Dwight L., Wirtz R., and White N. A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate. J Pharm Biomed Anal 24 (2000) 65-70
78. Green M., Mount D., and Wirtz R. Authentication of artemether, artesunate and dihydroartemisinin antimalarial tablets using a simple colorimetric method. Trop Med Int Health 6 (2001) 980-982
79. Green M., Newton P., and Fernandez F. Simple low-cost strategies to rapidly identify counterfeit drugs in developing countries. Combating pharmaceutical fraud and counterfeiting, SMI Conference Documentation (2003), SMI Publishing, London
80. Hu C., Zou W., Hu W., et al. Establishment of a fast chemical identification system for screening of counterfeit drugs of macrolide antibiotics. J Pharm Biomed Anal 40 (2005) 68-74
81. Cheung J., Chong S., Kitrenos J., and Fung H. Use of refractometers to detect controlled-substance tampering. Am J Hosp Pharm 48 (1991) 1488-1492
82. Larkin M. Hand-held device detects fake drugs. Lancet Infect Dis 2 (2002) 5
83. Green MD, Nettey H, Rojas OV, et al. Use of refractometry and colorimetry as field methods to rapidly assess antimalarial drug quality. J Pharm Biomed Anal (in press).
84. Sundar S., Sinha P., Agrawal N., et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 59 (1998) 139-143
85. Jordan D. Optical crystallographic characteristics of some USP drugs. J Pharm Sci 82 (1993) 1269-1271
86. Tillson A., and Eisenberg W. Tables for the identification of N.F.X crystalline substances by the microscopic-crystallographic method. J Pharm Sci 43 (1954) 760-767
87. Eisenberg W., and Tillson A. Identification of counterfeit drugs, particularly barbiturates and amphetamines by microscopic, chemical and instrumental techniques. J Forensic Sci 11 (1966) 529-551
88. Flurer C., and Wolnik K. Chemical profiling of pharmaceuticals by capillary electrophoresis in the determination of drug origin. J Chromatogr A 674 (1994) 153-163
89. Drasar P., and Moravcova J. Recent advances in analysis of Chinese medical plants and traditional medicines. J Chromatogr B 812 (2004) 3-21
90. Mulligan K., Brueggemeyer T., Crockett D., and Schepman J. Analysis of organic volatile impurities as a forensic tool for the examination of bulk pharmaceuticals. J Chromatogr B 686 (1996) 85-95
91. Cotter R. The new time-of-flight mass spectrometry. Anal Chem 71 (1999) 445A-451A
92. Scafi S., and Pasquini C. Identification of counterfeit drugs using near-infrared spectroscopy. Analyst 126 (2001) 2218-2224
93. Abrahamsson C., Johansson J., Andersson-Engels S., Svanberg S., and Folestad S. Time-resolved NIR spectroscopy for quantitative analysis of intact pharmaceutical tablets. Anal Chem 77 (2005) 1055-1059
94. Vankeirsbilck T., Vercauteren A., Baeyens W., et al. Applications of Raman spectroscopy in pharmaceutical analysis. Trends Anal Chem 21 (2002) 869-877
95. de Viej M, Vandenabeele P, Hall KA, et al. Fast detection and identification of counterfeit antimalarial tablets by Raman spectrospcopy. J Raman Spectroscopy (in press).
96. Takats Z., Wiseman J., Gologan B., and Cooks R. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science 306 (2004) 471-473
97. Cody R., Laramee J., and Durst H. Versatile new ion source for the analysis of materials in open air under ambient conditions. Anal Chem 77 (2005) 2297-2302
98. Wolff J., Thomson L., and Eckers C. Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan™ drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry. Rapid Comm Mass Spect 17 (2003) 215-221
99. Hall KA, Newton PN, Green MD et al. Characterization of counterfeit artesunate antimalarial tablets from Southeast Asia. Am J Trop Med Hyg (in press).
100. Fernández F., Cody R., Green M., et al. Characterization of solid counterfeit drug samples by desorption electrospray ionization and direct-analysis-in-real-time coupled to time-of-flight mass spectrometry. ChemMedChem 1 (2006) 702-705
101. Power G. Counterfeit pharmaceuticals. First Global Forum on Pharmaceutical Anticounterfeiting; Geneva, Switzerland; Sept 22-25, 2002.
102. McQuay H., and Moore R. Placebo. Postgrad Med J 81 (2005) 155-160
103. Newton P., Rozendaal J., Green M., and White N. Murder by fake drugs-time for international action. BMJ 324 (2002) 800-801
104. Issack M. Substandard drugs. Lancet 358 (2001) 1463
105. Suyavong P., Chaiyakunapruk N., and Patmasiriwat D. Estimation of clinical and economic consequences of counterfeit medicines in Lao PDR: an epidemiologic model (2005), Western Pacific Regional Office, WHO, Manila
106. Basco L., Ringwald P., Manene A., and Chandenier J. False chloroquine resistance in Africa. Lancet 350 (1997) 224
107. Petralanda I. Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region. Lancet 345 (1995) 1433
108. White N. Antimalarial drug resistance and combination chemotherapy. Phil Trans R Soc Lond B 354 (1999) 1-11
109. Shwe T., Nyein M., Yi W., and Mon A. Blood culture isolates from children admitted to Medical Unit III, Yangon Children's Hospital, 1998. Southeast Asian J Trop Med Public Health 33 (2002) 764-771
110. Laserson K., Kenyon A., Kenyon T., et al. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 5 (2001) 448-454
111. Laing R., Vrakking H., and Fourie B. Quality and stability of TB medicines: let the buyer beware!. Int J Tuberc Lung Dis 8 (2004) 1043-1044
112. Jambou R., Legrand E., Niang M., et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366 (2005) 1960-1963
113. Trouiller P., Torreele E., Olliaro P., et al. Drugs for neglected diseases: failure of the market and a public health failure. Trop Med Int Health 6 (2001) 945-951
114. USP. Ensuring the quality of medicines in low-income countries: an operational guide. http://www.uspdqi.org/pubs/other/ensuringQualityOperationalGuide.pdf (accessed July 16, 2006)
115. WHO. The Declaration of Rome. http://www.who.int/entity/medicines/services/counterfeit/RomeDeclaration.pdf (accessed July 16, 2006)
116. Chatterjee P. India's trade in fake drugs-bringing the counterfeiters to book. Lancet 357 (2001) 1776
117. Dhillon A. Bogus drug-makers warrant death penalty, Indian minister says. South China Morning Post (July 11, 2003) 11
118. Satchwell G. A sick business-counterfeit medicines and organised crime (2004), Stockholm Network, London
119. Anon. Jail for sellers of fake Viagra. Nation (Bangkok) (March 31, 2000)
120. Anon. GlaxoSmithKline case study. http://www.chinaiprlaw.com/english/news/news14.htm (accessed July 16, 2006)
121. Anon. WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Tech Rep Ser 885 (1999) 1-156
122. Wertheimer A., and Santella T. Counterfeit drugs: defining the problem and finding solutions. Expert Opin Drug Saf 4 (2005) 619-622
123. Phanouvong S. Registration, inspection and testing: how to prioritise. SEAM Conference; Dar es Salaam, Tanzania; Dec 10-12, 2003.
124. Syhakhang L., Stenson B., Wahlstrom R., and Tomson G. The quality of public and private pharmacy practices. A cross sectional study in the Savannakhet Province, Lao PDR. Eur J Clin Pharmacol 57 (2001) 221-227
125. Porter R. Health for sale. Quackery in England 1660-1850 (1989), Manchester University Press, Manchester & New York
126. Syhakhang L., Freusenthal S., Tomson G., and Wahlstrom R. Knowledge and perceptions of drug quality among drug sellers and consumers in Lao PDR. Health Policy Plan 19 (2004) 391-401
127. WHO. World Health Organisation-Western Pacific Region Rapid Alert System. http://218.111.249.28/ras/default.asp (accessed July 16, 2006)
128. Safemeds. Weekly news update. http://www.safemedicines.org (accessed Jan 10, 2006)
129. Anon. Bad medicine. Tempo (Jakata) (Sept 4-10, 2001)
130. Gibson L. Drug regulators study global treaty to tackle counterfeit drugs. BMJ 328 (2004) 486
131. Pecoul B., Chirac P., Trouiller P., and Pinel J. Access to essential drugs in poor countries. A lost battle?. JAMA 281 (1999) 361-367
132. Anon. Fake malaria drugs in Tanzania. Marketletter (Feb 20, 2001)
133. Myint H., Tipmanee P., Nosten F., et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 98 (2004) 73-81